{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:08:17Z","timestamp":1784704097684,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journalofnuclearcardiology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.nuclcard.2026.102727","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:03:42Z","timestamp":1778846622000},"page":"102727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imager"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9083-150X","authenticated-orcid":false,"given":"Bryton","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nuclcard.2026.102727_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCIMAGING.123.015259","article-title":"Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in Apo AI and AIV amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"Circ, Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102727_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1006\/jmbi.2000.4415","article-title":"Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution","volume":"306","author":"Sebasti\u00e3o","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.nuclcard.2026.102727_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.echo.2025.08.017","article-title":"Echocardiographic phenotypic differences between light-chain and transthyretin cardiac amyloid and relation to outcome","volume":"38","author":"Hamza","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.nuclcard.2026.102727_bib6","first-page":"159","article-title":"Amyloidosis-the diagnosis and treatment of an underdiagnosed disease","volume":"117","author":"Ihne","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.nuclcard.2026.102727_bib7","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nuclcard.2026.102727_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.17925\/HI.2024.18.1.5","article-title":"Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis","volume":"18","author":"Ioannou","year":"2024","journal-title":"Heart Int"},{"key":"10.1016\/j.nuclcard.2026.102727_bib9","doi-asserted-by":"crossref","DOI":"10.31083\/RCM46181","article-title":"Transthyretin cardiac amyloidosis and heart failure: state-of-the-Art review and practice guidance","volume":"26","author":"Bukhari","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.26599\/1671-5411.2023.05.006","article-title":"Cardiac amyloidosis: state-of-the-art review","volume":"20","author":"Bukhari","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib11","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nuclcard.2026.102727_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.acvd.2025.03.121","article-title":"Underestimated vascular dysfunction is a critical feature of the impaired cardiovascular profile in patients with transthyretin amyloidosis","volume":"118","author":"Monfort","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.nuclcard.2026.102727_bib13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nuclcard.2026.102727_bib16","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102727_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (Transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University amyloidosis center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102727_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy","volume":"45","author":"Hellenbart","year":"2025","journal-title":"The Journal of Human Pharmacology and Drug Therapy"},{"key":"10.1016\/j.nuclcard.2026.102727_bib24","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib25","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/anie.200351179","article-title":"Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action","volume":"42","author":"Razavi","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.nuclcard.2026.102727_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacl.2025.08.015","article-title":"Statin use in transthyretin amyloid cardiomyopathy: assessing tolerability and drug interaction risks with tafamidis","volume":"19","author":"Talasaz","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib28","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.nuclcard.2026.102727_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jacc.2025.09.013","article-title":"Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM: exploratory analysis from ATTRibute-CM","volume":"87","author":"Masri","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.nuclcard.2026.102727_bib33","series-title":"Attruby - full prescribing information (Reference ID: 5484268)","year":"2024"},{"key":"10.1016\/j.nuclcard.2026.102727_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nuclcard.2026.102727_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib38","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102727_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s44386-025-00015-4","article-title":"The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity","volume":"2","author":"Wall","year":"2025","journal-title":"npj Drug Discovery"},{"key":"10.1016\/j.nuclcard.2026.102727_bib44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.amjcard.2009.01.361","article-title":"Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis","volume":"103","author":"Austin","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.medcli.2020.04.031","article-title":"Light chain and transthyretin cardiac amyloidosis: clinical characteristics, natural history and prognostic factors","volume":"156","author":"Barge-Caballero","year":"2021","journal-title":"Med Clin"},{"key":"10.1016\/j.nuclcard.2026.102727_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/suab142.043","article-title":"Clinical presentation profiles and natural history of cardiac amyloidosis: long-term monocentric analysis (1990\u20132020)","volume":"23","author":"Porcari","year":"2021","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.nuclcard.2026.102727_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13506129.2021.1981281","article-title":"Utilization and tolerance of beta-blockers among patients with AL amyloidosis","volume":"29","author":"Briasoulis","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102727_bib50","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cardfail.2024.06.009","article-title":"Safety and efficacy of SGLT2 inhibitors for amyloid light-chain cardiomyopathy","volume":"30","author":"Lang","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib52","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib53","first-page":"146","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh","year":"2023","journal-title":"EXCLI J"},{"key":"10.1016\/j.nuclcard.2026.102727_bib54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1381612805666230110214512","article-title":"An overview of cyclophosphamide development and clinical applications","volume":"5","author":"Colvin","year":"1999","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nuclcard.2026.102727_bib55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nuclcard.2026.102727_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nuclcard.2026.102727_bib59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib60","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.nuclcard.2026.102727_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081605","article-title":"Immune therapies in AL Amyloidosis-A glimpse to the future","volume":"16","author":"Haran","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nuclcard.2026.102727_bib62","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/10428194.2024.2337803","article-title":"The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis","volume":"65","author":"Palladini","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nuclcard.2026.102727_bib63","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.nuclcard.2026.102727_bib64","series-title":"Prothena announces phase 3 AFFIRM-AL clinical trial for birtamimab in patients with AL amyloidosis did not meet primary endpoint","author":"Johnson","year":"2025"},{"key":"10.1016\/j.nuclcard.2026.102727_bib65","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.nuclcard.2026.102727_bib66","series-title":"Update on CARES phase III clinical programme of anselamimab in light chain amyloidosis","author":"Bowden","year":"2025"},{"key":"10.1016\/j.nuclcard.2026.102727_bib67","series-title":"Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis","author":"Capodanno","year":"2025"},{"key":"10.1016\/j.nuclcard.2026.102727_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-693","article-title":"Renal responses in a phase 1\/2 study of at-02, a novel pan-amyloid depleter ig fusion protein for the treatment of patients with AL amyloidosis","volume":"146","author":"Bell","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.nuclcard.2026.102727_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/011573403X240302230925043500","article-title":"Cardiac amyloidosis: a contemporary review of medical and surgical therapy","volume":"20","author":"Brownell","year":"2024","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.nuclcard.2026.102727_bib70","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nuclcard.2026.102727_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative 99mTc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102727_bib72","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102727_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040629","article-title":"Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide 124I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging","volume":"16","author":"Martin","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nuclcard.2026.102727_bib74","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10741-025-10493-3","article-title":"Positron emission tomography in cardiac amyloidosis: current evidence and future directions","volume":"30","author":"Aimo","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.nuclcard.2026.102727_bib75","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of Transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812600108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812600108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:42:52Z","timestamp":1784702572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107135812600108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"alternative-id":["S107135812600108X"],"URL":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102727","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imager","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology.","name":"copyright","label":"Copyright"}],"article-number":"102727"}}